KRAUSE

Managing all creative aspects of the ongoing ES-SCLC indication and 2024 launch of LS-SCLC... Leading the pan tumor team in all marketing aspects across 5 current IMFINZI indications and 5 launches through 2025... OPTUNE • TTFields device therapy in combination with pemetrexed + cisplatin/carboplatin for patients with unresectable MPM / US DTP and DTC - Novocure

Primary location: Gaylordsville United States